Carbapenems API’s for Antibiotic Resistance

A new publication is out called “May 19, 2016 – Tackling Drug-Resistant Infections Globally: final report and recommendations” and it highlights the antibiotic-resistant infections which are being seen for the 1st time in the U.S.

The review says “superbugs” could kill 10 million people each year and cost the world $100 trillion in lost economic output by 2050.

For the first time, a 49-year-old woman in Pennsylvania was infected with an E. coli which carried a gene for resistance against the drug colistin. She was successfully treated with an antibiotic. But, the Centers for Disease Control and Prevention, says “Antibiotic resistance is exploding in numbers as well as severity and the trends are alarming”.

Other countries have already seen multi-drug resistant superbugs that no antibiotic can fight. So far, the United States has not. But this sets the stage for that development, CDC officials said.


Alendronate: Helping Bones Get Stronger

Osteoporosis, Paget’s Disease and Alendronate

Alendronate-CAS-66376-36-1As part of the of drug family called bisphosphonates alendronate sodium works by increasing the thickness of bone by slowing down the cells that usually break down bone. This allows the cells that build bone to work more efficiently. Alendronate can help to reduce the incidence of osteoporosis-related fractures by making bones stronger.

Most patients can expect to see an increase in bone density after 3 months. Alendronate can help treat and prevent osteoporosis as long as it is taken consistently. Alendronate controls but does not cure osteoporosis and Paget’s disease of bone, but instead slows down the progression of these conditions.

Short-term use of Alendronate

In results from the Fracture Intervention Trial Long-term Extension (FLEX) study published in 2006 suggests that some women can eventually stop or take a break from taking Alendronate. That study included women who had taken Alendronate for at least five years. The participants were randomly assigned to continue the drug or switch to a placebo for five more years. Individuals who discontinued use showed a slow decline in bone density and a moderate increase in the risk for spine fractures. The rate of hip fracture, a far more serious injury, was the same in the both groups. Therefore, Alendronate treatment significantly reduced the incidence of injury and hospitalizations.

Patients taking Alendronate will need bone density tests every year or two after they discontinue use. If their bone density has declined significantly, an individual can always resume bisphosphonate therapy.

Alendronate Specifications

If dosage instructions are followed correctly by patient, it may help avoid damage to the esophagus or sores in the mouth when taking this medication. Dosage of Alendronate is available in pill starting at 5 to 70 mg and in oral solution at 70 mg as base. Instructions are simple, such as taking after getting up from bed and before eating or drinking anything.

LGM Pharma can assist clients as a supplier/distributor of Alendronate CAS# 66376-36-1 for research and development purposes. We specialize in supplying our customers with a wide range of APIs supported by integrated technical capabilities and access to complete regulatory DMF documentation, suitable for various R&D stages through commercial formulation production to various global pharmaceutical companies and academic research institutes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

Insulin Glargine gives New Hope for those with Type-2 Diabetes in New Clinical Trials

Insulin Glargine CAS# 160337-95-1:

Insulin GlargineInsulin Glargine is basically used as a treatment for Type-1 diabetes, a condition in which the body is not able to produce enough insulin, and as a result, is unable to control the amount of sugar in the blood stream. It is also used for the treatment of Type-2 diabetes where the body is unable to use insulin normally. Insulin Glargine is a synthetic version of insulin which is long lasting and works by replacing the insulin which is naturally produced by the body in order to move sugar from the blood to other parts of the body, where it is stored and used for energy.

In recent clinical trials, a fixed ratio combination of Insulin Glargine along with Lixisenatide, which is a GLP-1 RA was shown to have superior reduction in the average blood glucose levels as compared to past clinical trials. Overall, the fixed ratio combination showed to have a safety profile which reflected those of insulin Glargine and Lixisentide. According to the researchers, the meeting of the primary objectives of this clinical trial showcases the clinical value of Insulin Glargine. The study is said to be completed by Q3 of 2015.

As suppliers/distributors to researchers for the development of anti-diabetic drugs, LGM Pharma is able to assist you in the supply of Insulin Glargine CAS# 160337-95-1 API. Rest assured you will get premium quality API products along with the continuous support of our team throughout the R&D process.

General Drug Facts:

Insulin Glargine is an analogue of human insulin which has been modified to provide a consistent supply of plasma insulin in those people who have been diagnosed with Type-1 and Type-2 diabetes. While the drug could also be used for other medical conditions it is not to be used by patients who are experiencing diabetic ketoacidosis.

General Disease Facts:

Both Type-1 and Type-2 diabetes can pose major problems for the body, which is one of the reasons why diabetes is called “the silent killer”. Out of the two, Type-2 diabetes is considered as the most common form of diabetes. Those who have Type-2 diabetes are unable to use insulin in the proper way, resulting in an increase of sugar in the blood. While the pancreas does make more insulin at the beginning to make up for the loss, over time, it is unable to keep up and cannot make enough insulin to keep blood glucose levels at a normal range. The condition is also known as insulin resistance.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.

New Raltegravir Potassium Merck Agreement Proves to be a Major Improvement Over the Status Quo

Raltegravir potassium CAS 871038-72-1

Product name and CAS#: Raltegravir potassium CAS# 871038-72-1

Raltegravir potassium is a human immunodeficiency virus integrase strand transfer inhibitor. The drug is soluble in water and slightly soluble in ethanol and methanol as well. The pharmaceutically acceptable salt has been approved for the treatment of HIV-1.

The multinational pharmaceutical, Merck has signed an agreement with MPP (Medicines Patent Pool) to license its intellectual property relating to the formulation of Raltegravir, the company’s integrase HIV drug. According to reports, the new agreement should clear the way for cheaper formulations which can be developed for some middle income countries. The license is royalty free, and because of the terms of Agreement, drug manufacturers from around the world can now develop the drug formulations of Raltegravir along with other novel combinations.

By following in the footsteps of some of the biggest names in the pharmaceutical industry, Merck has now actually made it possible for manufacturers to sell pediatric versions of their medication, but only in licensed countries and under the agreed terms. This deal between the company and MPP is the first of its kind and has made it easier for people who are living with HIV in developing countries to get easy access to a cheap medication that can very well save their lives.

According to reports, the whole idea behind the deal is to lower the price of the drug, by facilitating in the drug’s development, especially for third world countries, which now have a better chance at surviving HIV. The Agreement covers 92 countries and according to the MPP, 98.1% of children with HIV are living in those developing countries.

As suppliers/distributors, LGM Pharma is able to assist you in acquiring Raltegravir potassium CAS# 871038-72-1 in order to carry out clinical trials specifying new formulation, dosages and delivery systems. Rest assured, we will provide you with premium quality API products along with the continuous support of our team throughout the entire R&D process.

General Disease Facts

HIV or human immunodeficiency virus is a virus that is responsible for the AIDS pandemic. The virus comes in two strains, HIV-1 and HIV-2. The main reason for this is that each time the HIV is able to replicate itself, small changes occur which lead to the various forms of HIV. Out of the two, the most predominant virus is HIV-1, and it’s the one that is generally talked about when discussing HIV or AIDS. This strain can also be classified into four groups, the most common one of the group being ‘M’ or ‘Major’.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13 (1). Any patent infringement and resulting liability is solely at buyer risk.

Saxagliptin Hydrochloride- The Most Efficient Substitute for Insulin

Saxagliptin hydrochloride CAS: 709031-78-7

The Hyderabad-based pharmaceutical company, Lee Pharma, has recently released a statement which says that Saxagliptin hydrochloride is the most effective substitute for insulin injectables for the treatment of Type-2 diabetes.

The statement was made while Lee Pharma said that the multinational company AstraZeneca, which it applied to for the patented diabetes medication Saxagliptin hydrochloride, was unable to keep up with the demand for the patented medicine. According to reports, Lee Pharma, which is a Rs. 200 crore drug company, filed an application back in June with the Controller of Patents in Mumbai seeking the license which is compulsory for the use of Saxagliptin hydrochloride.

Lee Pharma said the reason for filing the application and the growing need for Saxagliptin hydrochloride is that the population of Type-2 diabetes in India is currently around 60 million, and there were only four key anti-diabetes medications being used with Saxagliptin hydrochloride being one of them. The spokesperson from Lee Pharma also added that if one million patients were to be prescribed Saxagliptin, it would require the manufacturer to roll out around 365 million tablets each year to keep up with the demand. Currently, Lee Pharma has three major manufacturing units in Visakhapatnam and Hyderabad. The anti-diabetic medication they manufacturer is sold both locally and is also exported to 48 countries around the world.

As suppliers/distributors, LGM Pharma can assist you in acquiring Saxagliptin Hydrochloride CAS# 945667-22-1 to carry out your clinical trials, or for new formulation of dosages. We offer our customers the best premium quality APIs, with full compliance to strict guidelines and regulated by leading authorities. Apart from that, our customers also get our expert support throughout the R&D process.

General Drug Facts

Saxagliptin hydrochloride is a dipeptidyl peptidase-4 (DPP-4) inhibitor which is commonly used for the treatment of Type-2 diabetes. It works by increasing insulin levels that are released by your body, while decreasing the amount of sugar made by the natural process in a person’s body. The drug is usually used alongside a proper diet and exercise. Saxagliptin hydrochloride can be used alone and along with other medication.

General Disease Facts

Type-2 diabetes is a chronic disease in which a person has a high level of sugar in their blood. Type-2 diabetes is one of the most common forms of diabetes and effects more people worldwide than Type-1 diabetes. Type-2 diabetes can also develop in those people who are underweight, although it usually occurs in the elderly.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.